Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + Low-dose RT + IC in Advanced Nasopharyngeal Carcinoma
NCT05941741Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2024
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cadonilimab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression free survival at 3 years. Started Jan 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05941741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05941741.